XML 24 R12.htm IDEA: XBRL DOCUMENT
v3.20.4

Capital Stock | 12 Months Ended
--- | ---
Oct. 31, 2020
Equity [Abstract] |
Capital Stock | NOTE 6 – CAPITAL STOCK Common Stock On November 16, 2018, the Company issued 23,965 shares to one investor pursuant to their pre-emption rights under the terms of the private placement effected on or around January 29, 2018 for a purchase price of $105,446. On February 3, 2019, the Company issued a total of 7,143 shares to one of its directors for services rendered. These shares had a fair value of $42,289. On June 24, 2019, the Company issued 20,000 shares of common stock to consultants for services rendered. These shares had a fair value of $291,800. On September 16, 2019, the Company issued 25,000 shares of common stock pursuant to the terms of the Company’s Stock Incentive Plan 2017 to a director of one of our foreign subsidiaries for services rendered. These shares had a fair value of $260,500. On September 16, 2019, the Company issued a total of 5,357 of common stock pursuant to the terms of the Company’s Stock Incentive Plan 2017 to one of its employees for services rendered. These shares had a fair value of $55,820. On June 9, 2020, the Company issued 30,000 shares of common stock to consultants for services rendered. These shares had a fair value of $169,500. During the fiscal year ended October 31, 2020, the Company granted options to purchase an aggregate of 561,000 shares of common stock pursuant to the terms of the Plan to various eligible individuals. As a result, as of October 31, 2020, there were 352,612 shares available under the Plan. The following table presents stock option activity for the years ended October 31, 2020 and 2019.
Stock Options
|  | Total |  |  | Weighted Average Exercise Price |  |  | Exercisable |  |  | Weighted Average Exercise Price |  |  | Non-Vested |  |  | Weighted Average Exercise Price |
Outstanding at October 31, 2018 |  |  | - |  |  | $ | - |  |  |  | - |  |  | $ | - |  |  |  | - |  |  | $ | - |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Vested |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercises |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Forfeited or cancelled |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Outstanding at October 31, 2019 |  |  | - |  |  | $ | - |  |  |  | - |  |  | $ | - |  |  |  | - |  |  | $ | - |
Granted |  |  | 564,000 |  |  | $ | 4.65 |  |  |  | - |  |  |  | - |  |  |  | 564,000 |  |  | $ | 4.65 |
Vested |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercises |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Forfeited or cancelled |  |  | (3,000 | ) |  | $ | 4.65 |  |  |  | - |  |  |  | - |  |  |  | (3,000 | ) |  | $ | 4.65 |
Outstanding at October 31, 2020 |  |  | 561,000 |  |  | $ | 4.65 |  |  |  | - |  |  |  | - |  |  |  | 561,000 |  |  | $ | 4.65 |
Aggregate Intrinsic Value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
October 31, 2019 |  | $ | - |  |  |  |  |  |  | $ | - |  |  |  |  |  |  | $ | - |  |  |  |  |
Aggregate Intrinsic Value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
October 31, 2020 |  | $ | 491,280 |  |  |  |  |  |  | $ | - |  |  |  |  |  |  | $ | - |  |  |  |  |
The intrinsic value as of October 31, 2020 was $491,280 and $0 for October 31, 2019. The total expense recognized by the Company during the year ended October 31, 2020 was $441,280. The expense in future years is $815,880. Preferred Stock Series A and Series C Preferred Stock The Company is authorized to issue 5,000,000 shares of preferred stock with a par value of $0.001 per share. We had previously designated 50,000 preferred shares as Series A preferred stock and 50,000 preferred shares as Series C preferred stock. Both series have since been eliminated and as of October 31, 2020 there were no Series A or Series C Preferred Stock issued or outstanding.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration